The FDA has announced a recall involving nearly 12 million bottles of Rohto eye drops over concerns about sterility. The action appears in an FDA enforcement report and involves Rohto Cooling Eye Drops products.
Based on the agency notice, the recall is classified as Class II. The issue cited is a lack of assurance of sterility, a significant concern for products intended for use in the eyes.
The short description indicates that eight product lines are affected by the recall. The enforcement report also describes the move as a voluntary recall, signaling that the manufacturer initiated the action rather than it being ordered by the agency.
The development places renewed attention on quality control for over-the-counter eye care products. For consumers and retailers, the key details are the scale of the recall, the sterility concern, and the fact that multiple Rohto product lines are included in the FDA listing.
